GlassScriptPhysician profile
Justin D Puckett
NPI 1205044146
$567,543.92
in general payments reported to CMS, 2019-2025
52 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $28K · 2021: $51K · 2022: $91K · 2023: $114K · 2024: $70K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $227K · Travel and Lodging: $41K · Consulting Fee: $30K · Food and Beverage: $12K · Honoraria: $7,538 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,400 · Education: $93.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $227,442.00 |
| Travel and Lodging | $40,968.09 |
| Consulting Fee | $29,889.00 |
| Food and Beverage | $11,905.36 |
| Honoraria | $7,538.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,400.00 |
| Education | $93.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $337,105.14 | 2019-2025 | Spravato, Xarelto, Invega Sustenna |
| Novo Nordisk INC | $89,670.79 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $89,564.34 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Axsome Therapeutics, INC. | $24,675.90 | 2022-2025 | Auvelity |
| Astellas Pharma US INC | $6,161.33 | 2019-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $5,607.76 | 2023-2025 | Quviviq, Quviviq |
| Allergan, INC. | $4,990.65 | 2019-2020 | |
| Abbvie INC. | $2,953.25 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $669.16 | 2019-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $533.12 | 2021-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $518.91 | 2019-2025 | |
| Amarin Pharma, INC. | $349.84 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $345.12 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $318.52 | 2021-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $292.80 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $287.00 | 2022-2025 | Rexulti |
| Amgen INC. | $271.71 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $251.10 | 2019-2025 | Arexvy, Shingrix, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $227.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $219.07 | 2020-2025 | Verquvo, Vaxneuvance, Belsomra |
| Sunovion Pharmaceuticals INC. | $204.95 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $201.20 | 2021 | |
| Exact Sciences Corporation | $192.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alkermes, INC. | $177.44 | 2019-2024 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $173.99 | 2021-2023 | Qelbree |
| Radius Health, INC. | $137.23 | 2020-2023 | Tymlos |
| Sk Life Science, INC. | $132.38 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $125.82 | 2019-2024 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $113.55 | 2022-2024 | |
| Dexcom, INC. | $107.69 | 2022-2025 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $97.64 | 2019-2023 | Prolastin-C Liquid |
| Xeris Pharmaceuticals, INC. | $81.15 | 2024-2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $75.88 | 2019 | |
| Vanda Pharmaceuticals INC. | $75.13 | 2022-2023 | Hetlioz |
| Mylan Specialty L.P. | $69.77 | 2019-2024 | Yupelri |
| Abbott Laboratories | $65.89 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Sumitomo Pharma America, INC. | $61.99 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $59.31 | 2020-2022 | |
| Eisai INC. | $36.78 | 2020-2021 | |
| Optos, INC. | $36.36 | 2021 | |
| Ardelyx, INC. | $35.11 | 2024-2025 | Ibsrela |
| Organogenesis INC. | $32.40 | 2021 | |
| Esperion Therapeutics, INC. | $29.34 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.15 | 2022 | |
| Collegium Pharmaceutical, INC. | $29.10 | 2021 | |
| Daiichi Sankyo INC. | $28.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.44 | 2021 | |
| Aimmune Therapeutics, INC. | $23.47 | 2025 | Zenpep |
| Kyowa Kirin, INC. | $19.88 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.71 | 2023 | Nuzyra |
| Vertex Pharmaceuticals Incorporated | $17.91 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Puckett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.